Drug Approval | July 02, 2022
Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Saumen is a postgraduate in management from IIM, Ahmedabad and an executive fellow in management from ISB, Hyderabad
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
Pharmapack trends are a key barometer of global device and packing opportunities in 2022
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Subscribe To Our Newsletter & Stay Updated
